Ascend Wellness Holdings (AAWH) Income from Non-Controlling Interests (2020)
Ascend Wellness Holdings' (AAWH) quarterly Income from Non-Controlling Interests came in at $501000.0 in Q3 2020, down 32.02% quarter-over-quarter from $737000.0 in Q2 2020.
Ascend Wellness Holdings (AAWH) Income from Non-Controlling Interests (2020) Analysis & Trends
Ascend Wellness Holdings' Income from Non-Controlling Interests history runs 1 years deep, the most recent figure standing at $501000.0 for Q3 2020.
- On a quarterly basis, Income from Non-Controlling Interests changed N/A year-over-year to $501000.0 in Q3 2020; TTM through Jun 2021 was $501000.0, a N/A change from a year earlier, with the FY2020 full-year figure at $1.6 million, up 218.63% from the prior year.
- Income from Non-Controlling Interests declined to $501000.0 in Q3 2020 per AAWH's latest filing, from $737000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $737000.0 in Q2 2020 and bottomed at $360000.0 in Q1 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 395,346.10 |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | -12.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Ascend Wellness Holdings | 78.95 Mn | 18.03 Mn | 44.88 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 501,000.00 |
| Jun 30, 2020 | 737,000.00 |
| Mar 31, 2020 | 360,000.00 |